Amalgamated Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Amalgamated Financial’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$22K	Buy	+1,306	New	+$24.2K	﹤0.01%	2721

Other funds holding TARS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Amalgamated Financial's TARS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2022: 1,306 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings.

51 funds tracked by Wall St. Rank hold TARS as of Q1 2022.

Amalgamated Financial held 1,306 shares of Tarsus Pharmaceuticals worth $22K as of Q1 2022.
Tarsus Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Tarsus Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2721 holding.
51 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.